Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tharimmune, Inc. (THAR : NSDQ)

• Company Description    Tharimmune Inc. is a biotechnology company. It involved in developing a portfolio of therapeutic candidates for rare immune, inflammatory and oncologic diseases. Tharimmune Inc., formerly known as Hillstream BioPharma Inc., is based in BRIDGEWATER, NJ. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $3.14 Daily Weekly Monthly 20 Day Moving Average: 31,259,516 shares Shares Outstanding: 5.69 (millions) Market Capitalization: $17.87 (millions) Beta: 1.56 52 Week High: $9.08 52 Week Low: $0.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 137.88% 133.70% 12 Week 119.58% 99.46% Year To Date 54.68% 37.67%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1200 Route 22 East Suite 2000 - Bridgewater,NJ 08807 USA ph: 908-270-8260 fax: - ir@tharimmune.com http://www.tharimmune.com

• General Corporate Information    Officers Randy Milby - Chief Executive Officer and Chairman Thomas Hess - Chief Financial Officer Lynne Bui - Director Leonard Mazur - Director Sireesh Appajosyula - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 432705309 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 5.69 Most Recent Split Date: 5.00 (0.07:1) Beta: 1.56 Market Capitalization: $17.87 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 36.11 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 73.55% vs. Previous Quarter: 35.35% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -1,239.20 03/31/25 - -489.33 12/31/24 - -270.03 ROA 06/30/25 - -365.06 03/31/25 - -264.34 12/31/24 - -186.82 Current Ratio 06/30/25 - 1.17 03/31/25 - 0.67 12/31/24 - 1.54 Quick Ratio 06/30/25 - 1.17 03/31/25 - 0.67 12/31/24 - 1.54 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.09 03/31/25 - -0.37 12/31/24 - 0.68 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©